Contentious Indian Pricing Orders Now In Court
This article was originally published in Scrip
A string of controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA) are believed to have been challenged in court, putting plans to enforce these rules in limbo, at least in specific cases.
You may also be interested in...
The Bombay High Court has stayed certain controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA), including one pertaining to transitioning "non-scheduled" medicines, as the pharmaceutical industry contests multiple regulatory changes in India.
WTO director general says pharma could have done more on voluntary licensing for COVID-19 vaccines and also calls for better transparency of pricing and contracts to ensure “a level playing field” when it comes to saving lives.
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.